{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:01:19Z","timestamp":1747166479514,"version":"3.40.5"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jtct.2024.01.077","type":"journal-article","created":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T06:47:52Z","timestamp":1706338072000},"page":"437.e1-437.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Allogeneic Hematopoietic Stem Cell Transplantation for Mature T\/NK-Cell Lymphomas in Children"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1216-817X","authenticated-orcid":false,"given":"Maria","family":"Klimentova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Perminova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0520-5630","authenticated-orcid":false,"given":"Larisa","family":"Shelikhova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulia","family":"Abugova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daria","family":"Kobyzeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6148-7209","authenticated-orcid":false,"given":"Dmitry","family":"Pershin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry","family":"Balashov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Myakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0016-6698","authenticated-orcid":false,"given":"Alexei","family":"Maschan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1735-0093","authenticated-orcid":false,"given":"Michael","family":"Maschan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.jtct.2024.01.077_bib0001","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.jtct.2024.01.077_bib0002","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2024.01.077_bib0003","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3322\/caac.21589","article-title":"The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management","volume":"70","author":"Marchi","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"10.1016\/j.jtct.2024.01.077_bib0004","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3324\/haematol.2009.008250","article-title":"Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy","volume":"94","author":"Falini","year":"2009","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jtct.2024.01.077_bib0005","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/pbc.21293","article-title":"Peripheral T-cell lymphoma in childhood: population-based experience in the United Kingdom over 20 years","volume":"50","author":"Windsor","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.jtct.2024.01.077_bib0006","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/pbc.22329","article-title":"Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan","volume":"54","author":"Kobayashi","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"14","key":"10.1016\/j.jtct.2024.01.077_bib0007","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1200\/JCO.2004.12.032","article-title":"Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: A cohort study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"22","author":"Mounier","year":"2004","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.jtct.2024.01.077_bib0008","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2024.01.077_bib0009","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2024.01.077_bib0010","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma","volume":"9","author":"Ernst","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.jtct.2024.01.077_bib0011","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2024.01.077_bib0012","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00277-018-3559-3","article-title":"Outcomes of myeloablative peripheral blood stem cell transplantation for non-complete remission patients with relapsed\/refractory peripheral T cell lymphomas","volume":"98","author":"Gu","year":"2019","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.jtct.2024.01.077_bib0013","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/pbc.24722","article-title":"Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation","volume":"60","author":"Giulino-Roth","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"10.1016\/j.jtct.2024.01.077_bib0014","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/MPH.0b013e3182707592","article-title":"Peripheral T-cell lymphoma in children and adolescents: a single-institution experience","volume":"34","author":"Al Mahmoud","year":"2012","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2024.01.077_bib0015","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2006.06004.x","article-title":"Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents\u2014a Berlin-Frankfurt-M\u00fcnster group report","volume":"133","author":"Woessmann","year":"2006","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.jtct.2024.01.077_bib0016","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/bjh.13167","article-title":"Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan","volume":"168","author":"Fukano","year":"2015","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2024.01.077_bib0017","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbmt.2009.09.021","article-title":"Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents","volume":"16","author":"Gross","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15_suppl","key":"10.1016\/j.jtct.2024.01.077_bib0018","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2019.37.15_suppl.7503","article-title":"First-line therapy of T-cell lymphoma: allogeneic or autologous transplantation for consolidation\u2014final results of the AATT study","volume":"37","author":"Shmitz","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2024.01.077_bib0019","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/leu.2014.79","article-title":"Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma","volume":"28","author":"Corradini","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.jtct.2024.01.077_bib0020","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2141.2010.08210.x","article-title":"Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas","volume":"150","author":"Shustov","year":"2010","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jtct.2024.01.077_bib0021","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/sj.bmt.1705036","article-title":"Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma","volume":"36","author":"Wulf","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2024.01.077_bib0022","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.01.077_bib0023","first-page":"1","article-title":"Allogeneic hematopoietic stem cell transplantation for NK\/T-cell lymphoma: an international collaborative analysis","volume":"14","author":"Berning","year":"2023","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jtct.2024.01.077_bib0024","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2024.01.077_bib0025","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.bbmt.2014.12.031","article-title":"NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report","volume":"21","author":"Shulman","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2024.01.077_bib0026","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/s41409-020-01128-2","article-title":"T-cell tracking, safety, and effect of low-dose donor memory T-cell infusions after \u03b1\u03b2 T cell-depleted hematopoietic stem cell transplantation","volume":"56","author":"Blagov","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2024.01.077_bib0027","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41409-017-0035-y","article-title":"Low-dose donor memory T-cell infusion after TCR alpha\/beta depleted unrelated and haploidentical transplantation: results of a pilot trial","volume":"53","author":"Maschan","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2024.01.077_bib0028","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41409-021-01232-x","article-title":"Safety and efficacy of the low-dose memory (CD45RA-depleted) donor lymphocyte infusion in recipients of \u03b1\u03b2 T cell-depleted haploidentical grafts: results of a prospective randomized trial in high-risk childhood leukemia","volume":"56","author":"Dunaikina","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2024.01.077_bib0029","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1182\/blood.V80.11.2938.2938","article-title":"Bone marrow transplantation for peripheral T-cell lymphoma in children and adolescents","volume":"80","author":"Gordon","year":"1992","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2024.01.077_bib0030","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2024.01.077_bib0031","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbmt.2008.04.004","article-title":"Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience","volume":"14","author":"Chen","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2024.01.077_bib0032","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.jtct.2024.01.077_bib0033","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"D'Amore","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2024.01.077_bib0034","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/annonc\/mdl466","article-title":"The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience","volume":"18","author":"Rodr\u00edguez","year":"2007","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2024.01.077_bib0035","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.jtct.2024.01.077_bib0036","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jtct.2024.01.077_bib0037","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2141.2010.08298.x","article-title":"Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma","volume":"150","author":"D'Amore","year":"2010","journal-title":"Br J Haematol"},{"issue":"13","key":"10.1016\/j.jtct.2024.01.077_bib0038","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1182\/blood-2011-01-329441","article-title":"High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia\/lymphoma offers curative option with subsequent stem cell transplantation","volume":"118","author":"G\u00f6kbuget","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2024.01.077_bib0039","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clml.2012.01.010","article-title":"Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study","volume":"12","author":"Foss","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"10.1016\/j.jtct.2024.01.077_bib0040","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2024.01.077_bib0041","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jtct.2023.10.013","article-title":"Progress and pitfalls of chimeric antigen receptor T cell immunotherapy against T cell malignancies","volume":"30","author":"Angelos","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.01.077_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1118681","article-title":"CAR-iNKT cells targeting clonal TCRV\u03b2 chains as a precise strategy to treat T cell lymphoma","volume":"14","author":"Rowan","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2024.01.077_bib0043","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ymthe.2022.09.003","article-title":"Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies","volume":"31","author":"Watanabe","year":"2023","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.jtct.2024.01.077_bib0044","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood."}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724001738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724001738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T19:14:31Z","timestamp":1745003671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724001738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2666636724001738"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.01.077","relation":{},"ISSN":["2666-6367"],"issn-type":[{"type":"print","value":"2666-6367"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic Hematopoietic Stem Cell Transplantation for Mature T\/NK-Cell Lymphomas in Children","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.01.077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}